1
00:00:02,520 --> 00:00:08,920
Speaker 1: Bloomberg Audio Studios, podcasts, radio news talk us through the

2
00:00:08,960 --> 00:00:11,600
Speaker 1: main growth drivers that you see when you take a

3
00:00:11,600 --> 00:00:13,120
Speaker 1: look over the course of this year.

4
00:00:14,320 --> 00:00:16,960
Speaker 2: Yeah, first, Katie, thanks for having us on this morning.

5
00:00:17,920 --> 00:00:21,079
Speaker 2: You know, in terms of the growth drivers, we really

6
00:00:21,079 --> 00:00:24,840
Speaker 2: think there's two or three major things going on. One, unfortunately,

7
00:00:24,920 --> 00:00:28,520
Speaker 2: is still all of the chronic care disease management that's

8
00:00:28,520 --> 00:00:31,640
Speaker 2: occurring in the country. You know, type two diabetes at

9
00:00:31,640 --> 00:00:36,199
Speaker 2: an all time high, autoimmune disorders, cancer rates, younger and

10
00:00:36,240 --> 00:00:39,520
Speaker 2: younger patients being diagnosed with cancer, colon cancer in particular.

11
00:00:40,240 --> 00:00:43,040
Speaker 2: So all of this is leading to a lot of

12
00:00:43,120 --> 00:00:46,880
Speaker 2: testing as you can imagine, and helping people diagnose, helping

13
00:00:46,880 --> 00:00:50,199
Speaker 2: people figure out what the right therapy they should select,

14
00:00:50,479 --> 00:00:53,920
Speaker 2: and then actually monitoring the disease. Now at the other

15
00:00:54,040 --> 00:00:55,760
Speaker 2: end of the spectrum, and this is really a more

16
00:00:55,920 --> 00:01:00,160
Speaker 2: recent phenomenon, is all the new testing from a consumer

17
00:01:00,280 --> 00:01:04,520
Speaker 2: health standpoint, So you know, prevention is all about doing

18
00:01:04,600 --> 00:01:09,480
Speaker 2: something before the symptoms set in, and between our own

19
00:01:09,520 --> 00:01:13,399
Speaker 2: consumer health offering and then partnerships that we've developed in

20
00:01:13,440 --> 00:01:17,400
Speaker 2: the industry, we are really powering the wellness industry today.

21
00:01:17,520 --> 00:01:21,600
Speaker 2: So our relationships with Function Health, our relationships with WOOP,

22
00:01:21,640 --> 00:01:26,120
Speaker 2: with Aura, we're trying to make lab testing ubiquitous to consumers,

23
00:01:26,840 --> 00:01:30,759
Speaker 2: especially those that really have a focus on prevention and wellness.

24
00:01:31,319 --> 00:01:33,280
Speaker 2: But really it's those two things, Katie, that are really

25
00:01:33,360 --> 00:01:34,319
Speaker 2: driving the growth.

26
00:01:34,720 --> 00:01:36,640
Speaker 1: Well, I'm glad you brought up consumer health and some

27
00:01:36,720 --> 00:01:39,240
Speaker 1: of the partnerships you have Loop and AURA being some

28
00:01:39,280 --> 00:01:42,520
Speaker 1: of them. You also have partnerships with HYMNS and Function Health.

29
00:01:42,760 --> 00:01:45,320
Speaker 1: I see as well. How do you see that part

30
00:01:45,360 --> 00:01:48,560
Speaker 1: of the business evolving. How meaningful of a growth driver

31
00:01:49,000 --> 00:01:49,560
Speaker 1: can that be?

32
00:01:51,000 --> 00:01:53,880
Speaker 2: Yeah, So to put all of that in context, between

33
00:01:53,880 --> 00:01:57,640
Speaker 2: our own direct business, our own consumer direct business, plus

34
00:01:57,640 --> 00:02:01,240
Speaker 2: our partnerships with all those that you mentioned, it's about

35
00:02:01,240 --> 00:02:04,400
Speaker 2: a two hundred and fifty million dollars segment and you know,

36
00:02:04,480 --> 00:02:07,560
Speaker 2: we did eleven billion dollars last year, so it's meaningful.

37
00:02:08,280 --> 00:02:11,880
Speaker 2: What's more meaningful is that segment grew it over thirty

38
00:02:11,919 --> 00:02:15,040
Speaker 2: percent last year, and we expect it to continue to grow,

39
00:02:15,200 --> 00:02:18,040
Speaker 2: you know, you know, north of twenty percent this year.

40
00:02:18,680 --> 00:02:22,120
Speaker 2: And again, what we're seeing is just consumers taking more

41
00:02:22,240 --> 00:02:26,840
Speaker 2: interest in their health. With this notion of let's prevent disease,

42
00:02:26,919 --> 00:02:28,800
Speaker 2: let's try to get in front of that. You know,

43
00:02:28,840 --> 00:02:31,960
Speaker 2: if we look at our business today, about two thirds

44
00:02:31,960 --> 00:02:36,880
Speaker 2: of it is diagnosis of disease, you know, treatment of disease,

45
00:02:36,960 --> 00:02:39,840
Speaker 2: treatment monitoring, and really only a third of our business

46
00:02:39,960 --> 00:02:44,000
Speaker 2: is prevention and wellness, general health and wellness testing. Honestly,

47
00:02:44,160 --> 00:02:47,120
Speaker 2: I hope over the next day decade we can flip that.

48
00:02:47,320 --> 00:02:50,280
Speaker 2: I really hope that we can be two thirds prevention

49
00:02:50,440 --> 00:02:53,399
Speaker 2: and wellness and then a third of chroduct care management.

50
00:02:53,600 --> 00:02:55,799
Speaker 1: When you zoom out a bit, what are you seeing

51
00:02:55,800 --> 00:02:58,160
Speaker 1: in terms of trends when it comes to what types

52
00:02:58,200 --> 00:03:00,480
Speaker 1: of tests are being asked for and ordered.

53
00:03:01,760 --> 00:03:06,360
Speaker 2: Yeah, Alzheimer's Katie is a very very important set of

54
00:03:06,400 --> 00:03:10,240
Speaker 2: tests that we now offer. You know, before blood based

55
00:03:10,280 --> 00:03:15,240
Speaker 2: biomarkers came to fruition with respect to Alzheimer's really the

56
00:03:15,280 --> 00:03:19,799
Speaker 2: gold standard where cognitive tests that physicians perform and then

57
00:03:19,960 --> 00:03:23,239
Speaker 2: they would move that patient directly into imaging, whether that's

58
00:03:23,240 --> 00:03:26,680
Speaker 2: a pet CT image or an MRI image. And today

59
00:03:26,720 --> 00:03:31,160
Speaker 2: what we're seeing is there's blood based biomarkers for amyloid

60
00:03:31,200 --> 00:03:34,360
Speaker 2: pop plaque, for what we call these TAO bundles, and

61
00:03:34,600 --> 00:03:38,160
Speaker 2: you're actually going to detect Alzheimer's at a much earlier

62
00:03:38,200 --> 00:03:42,000
Speaker 2: stage than what you would see in imaging and some

63
00:03:42,080 --> 00:03:44,320
Speaker 2: of the new therapies that have been brought to market

64
00:03:44,400 --> 00:03:48,320
Speaker 2: by Eastside and by Lilly. These therapies generally work really

65
00:03:48,360 --> 00:03:52,120
Speaker 2: really well at the earliest stages of disease on set.

66
00:03:52,520 --> 00:03:55,960
Speaker 2: So these biomarkers are playing a very very important role today.

67
00:03:56,360 --> 00:04:00,279
Speaker 2: We position these blood based tests with primary care physicians

68
00:04:00,320 --> 00:04:03,880
Speaker 2: as well as neurologists. You know today, if you have

69
00:04:04,000 --> 00:04:07,160
Speaker 2: symptoms of Alzheimer's it can take upwards of six to

70
00:04:07,240 --> 00:04:10,080
Speaker 2: eight months to get in to see a memory care specialist,

71
00:04:10,640 --> 00:04:13,280
Speaker 2: and patients just don't want to wait that long because again,

72
00:04:13,320 --> 00:04:16,279
Speaker 2: there's therapies available if you are diagnosed.

73
00:04:16,440 --> 00:04:18,359
Speaker 1: Because you think about what's going on at some of

74
00:04:18,400 --> 00:04:22,560
Speaker 1: your peer diagnostics companies. Oncology testing has been driving just

75
00:04:23,080 --> 00:04:27,200
Speaker 1: rapid growth. So how does Quest position itself in that space.

76
00:04:27,240 --> 00:04:31,279
Speaker 1: I know that you recently bought Haystack Oncology, for example,

77
00:04:31,320 --> 00:04:35,560
Speaker 1: but is that an area where you would consider additional deals?

78
00:04:35,920 --> 00:04:39,200
Speaker 2: Yeah, first, Katie, it's a very very important part of

79
00:04:39,200 --> 00:04:43,120
Speaker 2: our business today. Most people don't know, but Quest Diagnostics

80
00:04:43,360 --> 00:04:47,800
Speaker 2: has a very large anatomical pathology business. Anatomical pathology is

81
00:04:48,480 --> 00:04:52,480
Speaker 2: when specimens are cut outside cut from the human body.

82
00:04:52,360 --> 00:04:56,760
Speaker 2: They're tissue samples, and so we have a very We

83
00:04:56,800 --> 00:05:00,719
Speaker 2: have the largest anatomical pathology business in the country where

84
00:05:01,080 --> 00:05:04,760
Speaker 2: we make diagnoses of cancer every single day. Now, once

85
00:05:04,800 --> 00:05:08,719
Speaker 2: you have that tumor specimen, there's several follow on tests

86
00:05:08,760 --> 00:05:11,800
Speaker 2: that are very important. The first being what type of

87
00:05:11,839 --> 00:05:15,640
Speaker 2: therapy should be used to treat that cancer after treatment

88
00:05:15,800 --> 00:05:19,600
Speaker 2: or potentially right after surgery. The next question is did

89
00:05:19,640 --> 00:05:22,520
Speaker 2: the surgeon get it all or did the chemotherapy eradicate

90
00:05:22,600 --> 00:05:25,279
Speaker 2: that disease? And we have a task you mentioned, the

91
00:05:25,279 --> 00:05:30,120
Speaker 2: Haystack minimally residual disease testing that looks for very very

92
00:05:30,160 --> 00:05:33,440
Speaker 2: small remnants of the cancer that may remain either post

93
00:05:33,480 --> 00:05:37,640
Speaker 2: surgery or post chemotherapy. So it's a growing portion of

94
00:05:37,640 --> 00:05:41,280
Speaker 2: our portfolio of testing today. Now, in addition, we offer

95
00:05:41,360 --> 00:05:45,400
Speaker 2: a lot of routine cancer tests PSA screening all sorts

96
00:05:45,400 --> 00:05:48,240
Speaker 2: of different types of cancer markers at the screening phase.

97
00:05:48,279 --> 00:05:53,880
Speaker 2: So all told, cancer of our eleven billion dollar portfolio today,

98
00:05:54,040 --> 00:05:56,919
Speaker 2: cancer in its entirety is about a billion dollars of

99
00:05:56,960 --> 00:05:57,680
Speaker 2: our portfolio.